SCHEMBL30608828

SCHEMBL30608828

Cc1cc(NC(=O)NCc2ccc3c(c2)CN(C2CCC(=O)NC2=O)C3=O)ccc1OCc1ccc(CN)cc1

nearest known ligand 0.70

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 15/20 0.70
GSPT1 P15170 4/20 0.70
IKZF3 Q9UKT9 3/20 0.70
DDB1 Q16531 2/20 0.70
CSNK1A1 P48729 6/20 0.52
CYP2C19 P33261 1/20 0.51
KCNH2 Q12809 1/20 0.51
F11 P03951 1/20 0.47
IKZF2 Q9UKS7 7/20 0.47
HDAC3 O15379 1/20 0.47
HDAC1 Q13547 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26185815 1.00 CRBN (0.70) CRBNGSPT1IKZF3DDB1CSNK1A1
SCHEMBL26185830 0.91 CRBN (0.64) CRBNGSPT1IKZF3DDB1CSNK1A1
SCHEMBL26185827 0.91 CRBN (0.72) CRBNGSPT1IKZF3DDB1CSNK1A1
SCHEMBL30608814 0.91 CRBN (0.64) CRBNGSPT1IKZF3DDB1CSNK1A1
SCHEMBL26185802 0.89 CRBN (0.66) CRBNGSPT1IKZF3DDB1CSNK1A1
Hydrochloric Acid SCHEMBL31434497 0.88 CRBN (0.65) CRBNGSPT1IKZF3DDB1CSNK1A1
SCHEMBL30608808 0.86 CRBN (0.62) CRBNGSPT1IKZF3DDB1CSNK1A1
SCHEMBL26185803 0.86 CRBN (0.62) CRBNGSPT1IKZF3DDB1CSNK1A1
SCHEMBL1413700 0.86 CRBN (0.86) CRBNGSPT1IKZF3DDB1CSNK1A1
SCHEMBL62578 0.86 CRBN (0.80) CRBNGSPT1IKZF3DDB1CSNK1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4508044-A1 NOVEL GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS Bristol-Myers Squibb Company (US) 2025-02-19 EP claimed
CN-119013266-A Novel GSPT compounds and methods of use of novel compounds 百时美施贵宝公司 2024-11-22 CN claimed
WO-2023201282-A1 NOVEL GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2023-10-19 WO claimed
US-20250092012-A1 GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2025-03-20 US disclosed
EP-4508044-A1 NOVEL GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS Bristol-Myers Squibb Company (US) 2025-02-19 EP disclosed
US-12187699-B2 GSPT1 compounds and methods of use of the novel compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2025-01-07 US disclosed
CN-119013266-A Novel GSPT compounds and methods of use of novel compounds 百时美施贵宝公司 2024-11-22 CN disclosed
US-20230331693-A1 GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2023-10-19 US disclosed
WO-2023201282-A1 NOVEL GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2023-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331693-A1 GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS GSPT1, GSS, GSPT2 CRBN 3671/4885GSPT1 1/4885IKZF3 4747/4885
US-20250092012-A1 GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS GSPT1, GSS, GSPT2 CRBN 3671/4885GSPT1 1/4885IKZF3 4747/4885
US-12187699-B2 GSPT1 compounds and methods of use of the novel compounds GSPT1, GSS, GSPT2 CRBN 3671/4885GSPT1 1/4885IKZF3 4747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.